A few months after Summit Therapeutics shocked the oncology world with an early claim that its lung cancer drug ivonescimab ...

Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add ...

An influential member in Congress is slated to publicly disavow the closely watched Biosecure Act ahead of a planned House ...

A federal judge in Maryland has rejected a request from drugmakers and industry group PhRMA to stop a Maryland law that would ...

Cam­bridge, MA-based start­up Vesi­gen Ther­a­peu­tics is lay­ing off staff and “eval­u­at­ing strate­gic op­tions,” CEO ...

When looking to the future of the drug industry, the allure of Boston is strong. This week, the Japanese drugmaker Astellas ...

Travere Therapeutics won full approval for Filspari, which treats a rare autoimmune disease that affects the kidneys.

Amid the brouhaha over Alnylam’s disappointing and perhaps confusing HELIOS-B data presentation last week, competitor ...

Milestone’s calcium channel blocker succeeded in a late-phase trial in China in people with an abnormal heart rhythm disorder ...

Plus, news about the Gladstone Institutes, ImmunityBio, Keen Vision Acquisition Corporation and Medera: Basilea Pharmaceutica earns $25M milestone from Pfizer: The payment was triggered after the ...

Bicara Ther­a­peu­tics and Zenas Bio­Phar­ma are now a step clos­er to kick­ing open a mi­ni-IPO win­dow for drug de­vel­op­ers this fall.

GSK’s Nucala passed a late-phase test in chronic obstructive pulmonary disorder, setting the stage for a showdown against a ...